These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 29096172)

  • 1. β-Lactamase inhibitors: what you really need to know.
    Ambrose PG; Lomovskaya O; Griffith DC; Dudley MN; VanScoy B
    Curr Opin Pharmacol; 2017 Oct; 36():86-93. PubMed ID: 29096172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What the Clinical Microbiologist Should Know About Pharmacokinetics/Pharmacodynamics in the Era of Emerging Multidrug Resistance: Focusing on β-Lactam/β-Lactamase Inhibitor Combinations.
    Abodakpi H; Wanger A; Tam VH
    Clin Lab Med; 2019 Sep; 39(3):473-485. PubMed ID: 31383269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on β-lactamase inhibitor discovery and development.
    Docquier JD; Mangani S
    Drug Resist Updat; 2018 Jan; 36():13-29. PubMed ID: 29499835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics-pharmacodynamics of β-lactamase inhibitors: are we missing the target?
    Monogue ML; Nicolau DP
    Expert Rev Anti Infect Ther; 2019 Aug; 17(8):571-582. PubMed ID: 31340665
    [No Abstract]   [Full Text] [Related]  

  • 5. β-Lactamase inhibitor peptides as the new strategies to overcome bacterial resistance.
    Silva ON; Franco OL; Porto WF
    Drugs Today (Barc); 2018 Dec; 54(12):737-746. PubMed ID: 30596392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Game Changers: New β-Lactamase Inhibitor Combinations Targeting Antibiotic Resistance in Gram-Negative Bacteria.
    Bush K
    ACS Infect Dis; 2018 Feb; 4(2):84-87. PubMed ID: 29232103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. β-Lactamase Inhibitors To Restore the Efficacy of Antibiotics against Superbugs.
    González-Bello C; Rodríguez D; Pernas M; Rodríguez Á; Colchón E
    J Med Chem; 2020 Mar; 63(5):1859-1881. PubMed ID: 31663735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens.
    Bush K
    Int J Antimicrob Agents; 2015 Nov; 46(5):483-93. PubMed ID: 26498989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial Resistance in the Intensive Care Unit: A Focus on Gram-Negative Bacterial Infections.
    MacVane SH
    J Intensive Care Med; 2017 Jan; 32(1):25-37. PubMed ID: 26772199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A focused fragment library targeting the antibiotic resistance enzyme - Oxacillinase-48: Synthesis, structural evaluation and inhibitor design.
    Akhter S; Lund BA; Ismael A; Langer M; Isaksson J; Christopeit T; Leiros HS; Bayer A
    Eur J Med Chem; 2018 Feb; 145():634-648. PubMed ID: 29348071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
    Cho JC; Fiorenza MA; Estrada SJ
    Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.
    Mohanty S; Singhal R; Sood S; Dhawan B; Das BK; Kapil A
    Indian J Med Res; 2005 Nov; 122(5):425-8. PubMed ID: 16456257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New promising β-lactamase inhibitors for clinical use.
    Olsen I
    Eur J Clin Microbiol Infect Dis; 2015 Jul; 34(7):1303-8. PubMed ID: 25864193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-lactam/beta-lactamase inhibitor combinations in empiric management of pediatric infections.
    Adam D
    J Int Med Res; 2002; 30 Suppl 1():10A-19A. PubMed ID: 11921490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.
    Nicolau DP
    Expert Opin Investig Drugs; 2015; 24(9):1261-73. PubMed ID: 26145447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo pharmacodynamics of piperacillin/tazobactam: implications for antimicrobial efficacy and resistance suppression with innovator and generic products.
    Rodriguez CA; Agudelo M; Zuluaga AF; Vesga O
    Int J Antimicrob Agents; 2017 Feb; 49(2):189-197. PubMed ID: 27988068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorogenic Probes/Inhibitors of β-Lactamase and their Applications in Drug-Resistant Bacteria.
    Ding Y; Li Z; Xu C; Qin W; Wu Q; Wang X; Cheng X; Li L; Huang W
    Angew Chem Int Ed Engl; 2021 Jan; 60(1):24-40. PubMed ID: 32592283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management.
    Kaye KS; Pogue JM
    Pharmacotherapy; 2015 Oct; 35(10):949-62. PubMed ID: 26497481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic resistance breakers: current approaches and future directions.
    Laws M; Shaaban A; Rahman KM
    FEMS Microbiol Rev; 2019 Sep; 43(5):490-516. PubMed ID: 31150547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A practical look at the clinical usefulness of the beta-lactam/beta-lactamase inhibitor combinations.
    Hart SM; Bailey EM
    Ann Pharmacother; 1996 Oct; 30(10):1130-40. PubMed ID: 8893121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.